#United States #Indianapolis #Zepbound #Eli Lilly #Foundayo

Eli Lilly's Groundbreaking Access Milestone in Obesity Care

Eli Lilly and Company is paving the way towards better obesity treatment access in America, setting an important milestone for millions of patients in need. Starting June 1, 2026, CVS Caremark, one of the largest pharmacy benefit managers in the nation, will begin to cover Foundayo. Similarly, coverage for Zepbound will resume across existing plans by October 1, 2026.

“This expansion is monumental for patients who have struggled with obesity and the effective treatments that have long been out of reach,” said Ilya Yuffa, Executive Vice President at Lilly USA. This change implies that eligible patients could pay as little as $25 per month for their medications. Those enrolled in Medicare Part D may also benefit, with potential costs as low as $50 starting July 1 through the Medicare GLP-1 Bridge program.

A Dual Approach to Obesity Management

With the expanding coverage, patients will have access to a broader range of FDA-approved obesity treatments. Foundayo stands out as the only once-daily GLP-1 pill, offering convenience since it can be taken at any time without food or water restrictions. Zepbound, being the most prescribed injectable weight management drug in the United States, provides another effective option in obesity care.

By offering diverse treatment mechanisms, Lilly acknowledges that no single solution fits everyone, thus putting power in the hands of both patients and healthcare providers. As Yuffa mentioned, “Broader coverage puts real choice in the hands of millions of Americans and their doctors.”

The Medications in Focus

Foundayo™ (orforglipron)

Foundayo is a small, non-peptide oral medication approved for adults with obesity or those struggling with related medical issues. It’s designed to facilitate weight loss and assist in long-term maintenance when combined with a reduced-calorie diet and increased physical activity. Its unique formulation allows for daily use without food intake restrictions.

Zepbound® (tirzepatide)

On the other hand, Zepbound is not only approved for adults experiencing obesity, but it also addresses moderate-to-severe obstructive sleep apnea linked to obesity. With its dual action targeting both appetite reduction and overall food intake, Zepbound stands out in the realm of obesity management solutions.

Both drugs come with a set of warnings; potential thyroid tumors and serious stomach issues are noted as risks. These details stress the importance of patient education and ongoing discussions with healthcare providers to ensure safe and effective treatment.

Clinical Trials and Demonstrated Efficacy

The efficacy of Foundayo is backed by the ATTAIN clinical trial program which has involved over 4,500 participants worldwide. Preliminary results show promising weight loss, with the highest dose leading to an average weight reduction of 27.3 pounds over 72 weeks. Similarly, results from the SURMOUNT-1 clinical trial have indicated Zepbound's effectiveness, showing significant average weight loss across different dosages.

A Step Forward But Not Without Cautions

Despite the promising news surrounding Eli Lilly’s expanded access to obesity medications, they remind potential users to remain vigilant and informed. Individuals planning to start either treatment are encouraged to have thorough discussions with their healthcare providers regarding the potential side effects and benefits tailored to their personal health journeys.

As we stand on the brink of a new era in obesity treatment in America, patients can stay informed about their coverage options and savings by visiting Foundayo.com and Zepbound.com. Continuous updates regarding coverage and costs will ensure that patients make informed decisions about their weight management strategies.

In an era where obesity management can be a complicated journey, Eli Lilly is committed to supporting both patients and providers through accessible therapies that could lead to meaningful interventions and improved health outcomes.